Found 14 matching trials
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma N/A This study is conducted to evaluate the efficacy, prognosis, adverse effect...
Show More Location
The Second Affiliated Hospital of Fujian Medical University
Learn More & Join Trial
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy PHASE2 The purpose of this study is to establish a prospective, single-center plat...
Show More Location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Learn More & Join Trial
Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC N/A Combination treatment with antiangiogenic agents and anti-programmed cell d...
Show More Location
Zhongshan Hospital, Fudan University
Learn More & Join Trial
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma NA PD-1 inhibitor plus anti-VEGFR has become the established standard first-li...
Show More Location
Guiping People's Hospital
Learn More & Join Trial
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade PHASE2 The study is an interventional phase II clinical trial aiming to evaluate t...
Show More Location
Peking University Cancer Hospital
Learn More & Join Trial
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis PHASE2 A prospective, single-center, phase II clinical study of adebrelimab combin...
Show More Status
Active Not Recruiting
Location
Chongqing University Cancer Hospital
Learn More & Join Trial
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma N/A The aim of this study is to the efficacy, prognosis, adverse effects, and f...
Show More Location
The Second Affiliated Hospital of Fujian Medical University
Learn More & Join Trial
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma PHASE2 This is a Phase II , Open-label , Investigator-initiated Trail of SBRT in C...
Show More Location
Multiple Locations
Learn More & Join Trial
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) PHASE2 Patients with advanced biliary tract malignant tumors who had not received ...
Show More Location
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Learn More & Join Trial
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC N/A The purpose of this study is to evaluate the safety and efficacy of transar...
Show More Learn More & Join Trial